Skip to main content
. Author manuscript; available in PMC: 2013 May 15.
Published in final edited form as: Biochem Pharmacol. 2012 Mar 3;83(10):1445–1455. doi: 10.1016/j.bcp.2012.02.021

Figure 5.

Figure 5

Activation of NR4A2 and different domains of NR4A2 by C-DIMs and 6-MP. Full length (GAL4-Nurr1, 20 ng) or truncated GAL4-Nurr1 containing the A/B domain (GAL4-Nurr1-AB, 20 ng) or C to F domains [GAL4-Nurr1-(C-F), 20 ng] was cotransfected with UASx5-Luc (200 ng) into Panc28 (A, C) or Panc1 (B, D) cells for 6 hr and then treated with 10 μM DIM-C-pPhI, -pPhBr, -pPhCF3, -pPhOCF3 or 50 μM 6-mercaptopurine (C, D) for 18 hr. Panc28 (E) or Panc1 (F) cells were transfected with 10 ng full/truncated GAL4-Nurr1 and 200 ng UASx5-Luc for 6 hr and pre-incubated with 20 μM kinase inhibitors PD98059 or LY294002 for 45 min and treated with 10 μM DIM-C-pPhBr for 18 hr. Luciferase activity was determined as described in the Materials and Methods. Results are expressed as means ± SD for at least three separate determinations for each treatment. *, P < 0.05, treatment vs. solvent control (DMSO). **, P < 0.05, kinase inhibitor and DIM-C-pPhBr cotreatment vs. DIM-C-pPhBr treatment.